Concepedia

Hu Liang

HL

Statistics

Publications

4

Citations

65

H-Index

4

Active since

2023

Affiliations

Sun Yat-sen University(Current)

Sun Yat-sen University Cancer Center

Sun Yat-sen Memorial Hospital

National Cancer Institute

National Institutes of Health

Hu Liang is an author at Sun Yat-sen University specializing in chemotherapy, oncology, and medicine.

Publications per year

2023–2025

4

Publications

4

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study

Nian Lu, Yao-Fei Jiang, Wei‐Xiong Xia et al. · EClinicalMedicine · 2023 · 18 citations · Full text

, , +14

Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial

Hu Liang, Yao-Fei Jiang, Guoying Liu et al. · Nature Communications · 2024 · 17 citations · Full text

, , +17

Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial

Guoying Liu, Yan-Fang Ye, Yao-Fei Jiang et al. · BMJ · 2024 · 16 citations · Full text

, , +17

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial

Yaofei Jiang, Wei-Xin Bei, Lin Wang et al. · BMC Medicine · 2025 · 14 citations · Full text

, , +17

1–4 of 4